AIDS
MCID: ACQ007
MIFTS: 66

Acquired Immunodeficiency Syndrome (AIDS)

Categories: Immune diseases, Infectious diseases

Aliases & Classifications for Acquired Immunodeficiency Syndrome

MalaCards integrated aliases for Acquired Immunodeficiency Syndrome:

Name: Acquired Immunodeficiency Syndrome 12 3 45 15 74
Acquired Immune Deficiency Syndrome 12 77 3 15
Aids 12 49
Acquired Immune Deficiency 12

Classifications:



External Ids:

Disease Ontology 12 DOID:635
MeSH 45 D000163
NCIt 51 C2851
SNOMED-CT 69 62479008
ICD10 34 B20
UMLS 74 C0001175

Summaries for Acquired Immunodeficiency Syndrome

Disease Ontology : 12 A Human immunodeficiency virus infectious disease that results in reduction in the numbers of CD4-bearing helper T cells below 200 per ��L of blood or 14% of all lymphocytes thereby rendering the subject highly vulnerable to life-threatening infections and cancers, has material basis in Human immunodeficiency virus 1 or has material basis in Human immunodeficiency virus 2, which are transmitted by sexual contact, transmitted by transfer of blood, semen, vaginal fluid, pre-ejaculate, or breast milk, transmitted by congenital method, and transmitted by contaminated needles. Opportunistic infections are common in people with AIDS.

MalaCards based summary : Acquired Immunodeficiency Syndrome, also known as acquired immune deficiency syndrome, is related to human immunodeficiency virus type 1 and pneumocystosis. An important gene associated with Acquired Immunodeficiency Syndrome is HCP5 (HLA Complex P5), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Rilpivirine and Darunavir have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and liver, and related phenotypes are cellular and homeostasis/metabolism

CDC : 3 Help

Wikipedia : 77 Human immunodeficiency virus infection and acquired immune deficiency syndrome (HIV/AIDS) is a spectrum... more...

Related Diseases for Acquired Immunodeficiency Syndrome

Diseases related to Acquired Immunodeficiency Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2033)
# Related Disease Score Top Affiliating Genes
1 human immunodeficiency virus type 1 32.1 B2M CCR2 CCR5 CD38 CD4 IFNG
2 pneumocystosis 31.5 ALB CD4 TNF
3 cytomegalovirus retinitis 31.2 CCR2 CCR5 CSF2 IFNG TNF
4 cytomegalovirus infection 31.2 B2M IL6 TNF
5 toxoplasmosis 31.1 CCR5 IFNG IL10 IL6 TNF
6 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 31.1 CCR5 CD4 IFNG IL10 IL2 ITIH4
7 meningoencephalitis 31.0 ALB B2M IL6
8 viral infectious disease 31.0 CCR5 CD4 IFNG IL10 IL2 IL6
9 meningitis 31.0 ALB IFNG IL10 IL6 TNF
10 cholangitis 30.9 ALB IL6 TNF
11 aspergillosis 30.8 CSF2 IFNG IL10 TNF
12 uveitis 30.8 IFNG IL10 TNF
13 pericarditis 30.8 IFNG IL6 TNF
14 arthritis 30.7 CSF2 IFNG IL10 IL6 TNF
15 burns 30.7 ALB CSF2 TNF
16 lymphadenitis 30.6 IFNG IL10 TNF
17 appendicitis 30.6 ALB IL10 IL6 TNF
18 leishmaniasis 30.6 IFNG IL10 RN7SL1 TNF
19 colitis 30.6 IFNG IL10 IL2 IL6 TNF
20 cutaneous leishmaniasis 30.6 IFNG IL10 TNF
21 variola major 30.6 IFNG IL2
22 osteomyelitis 30.5 IFNG IL10 IL6 TNF
23 visceral leishmaniasis 30.5 ALB IFNG IL10 IL2 TNF
24 endocarditis 30.5 ALB IL10 IL6 TNF
25 lymphoma, non-hodgkin, familial 30.4 B2M CD38 CSF2 IL2 MYC
26 angioimmunoblastic lymphadenopathy with dysproteinemia 30.4 IL6 TNF
27 peritonitis 30.4 ALB B2M IL10 IL6 TNF
28 hypersplenism 30.4 ALB CD4 IFNG
29 mucocutaneous leishmaniasis 30.4 CCR5 IL10 TNF
30 herpes zoster 30.3 HCP5 IFNG IL10 IL2
31 keratoconjunctivitis 30.3 IFNG IL2 TNF
32 paracoccidioidomycosis 30.3 IFNG IL10 IL2 IL6 TNF
33 chagas disease 30.3 CCR5 IFNG IL10 IL2 IL6 TNF
34 aids dementia complex 30.3 B2M ITIH4 TNF
35 pulmonary tuberculosis 30.2 IFNG IL10 IL2 TNF
36 allergic contact dermatitis 30.2 IFNG IL10 TNF
37 bronchiolitis 30.2 IFNG IL10 IL6 TNF
38 demyelinating disease 30.2 IFNG IL10 TNF
39 adult respiratory distress syndrome 30.2 IL10 IL6 TNF
40 arteries, anomalies of 30.2 ALB IL6 TNF
41 rheumatic heart disease 30.2 IL10 IL6 TNF
42 obstructive jaundice 30.2 ALB IL6 TNF
43 peripheral nervous system disease 30.2 ALB IL6 TNF
44 chlamydia 30.2 IFNG IL10 IL6 TNF
45 smallpox 30.2 CSF2 IFNG IL2 TNF
46 alopecia areata 30.1 IFNG IL2 TNF
47 trichosporonosis 30.1 CSF2 IFNG TNF
48 hemophagocytic lymphohistiocytosis 30.1 B2M IFNG IL10 TNF
49 multiple sclerosis 30.1 CCR5 IFNG IL10 IL2 IL6 TNF
50 end stage renal failure 30.1 ALB IL6 TNF

Graphical network of the top 20 diseases related to Acquired Immunodeficiency Syndrome:



Diseases related to Acquired Immunodeficiency Syndrome

Symptoms & Phenotypes for Acquired Immunodeficiency Syndrome

MGI Mouse Phenotypes related to Acquired Immunodeficiency Syndrome:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.36 ALB B2M CCR2 CCR5 CD38 CD4
2 homeostasis/metabolism MP:0005376 10.28 ALB B2M CCR2 CCR5 CD38 CD4
3 hematopoietic system MP:0005397 10.27 B2M CCR2 CCR5 CD38 CD4 CSF2
4 cardiovascular system MP:0005385 10.26 B2M CCR2 CCR5 CSF2 F9 IFNG
5 digestive/alimentary MP:0005381 10.24 ALB B2M CCR2 CCR5 CD4 IFNG
6 endocrine/exocrine gland MP:0005379 10.22 ALB B2M CD38 CD4 CSF2 IFNG
7 immune system MP:0005387 10.22 B2M CCR2 CCR5 CD38 CD4 CSF2
8 liver/biliary system MP:0005370 10.1 ALB B2M CCR2 CCR5 F9 IFNG
9 mortality/aging MP:0010768 10.07 ALB B2M CCR2 CCR5 CD4 CSF2
10 integument MP:0010771 9.97 B2M CD4 CSF2 IFNG IL10 IL6
11 neoplasm MP:0002006 9.93 ALB B2M CCR2 CCR5 CSF2 IFNG
12 no phenotypic analysis MP:0003012 9.5 CCR2 CD4 IFNG IL10 IL2 MYC
13 reproductive system MP:0005389 9.28 B2M CCR5 CSF2 IFNG IL10 IL2

Drugs & Therapeutics for Acquired Immunodeficiency Syndrome

Drugs for Acquired Immunodeficiency Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rilpivirine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 500287-72-9
2
Darunavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 206361-99-1, 635728-49-3 213039
3
Cobicistat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1004316-88-4
4
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 143491-57-0 60877
5
Tenofovir Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147127-20-6 464205
6
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52485-79-7 644073 40400
7
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 36791-04-5 37542
8
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 6493-05-6 4740
9
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 134678-17-4 60825
10
Abacavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 136470-78-5 441300 65140
11
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3056-17-5 18283
12
Rifabutin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 72559-06-9 46783538 6323490
13
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 155213-67-5 392622
14
Dolutegravir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1051375-16-6 54726191
15
Lopinavir Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 192725-17-0 92727
16
Zidovudine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 30516-87-1 35370
17
Efavirenz Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 154598-52-4 64139
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
19
Isoniazid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 54-85-3 3767
20
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable,Early Phase 1 564-25-0 54671203
21
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 723-46-6 5329
22
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 738-70-5 5578
23
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 376348-65-1 3002977
24
Methadone Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76-99-3 4095
25
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 93-14-1 3516
26
Artemether Approved Phase 4,Phase 3,Phase 1,Not Applicable 71963-77-4 68911 119380
27
Lumefantrine Approved Phase 4,Phase 3,Phase 1,Not Applicable 82186-77-4 6437380
28
Rifampicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13292-46-1 5381226 5458213
29
Nevirapine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 129618-40-2 4463
30
Didanosine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69655-05-6 50599
31
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159989-64-7 64143
32
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
33
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
34
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
35
Amprenavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 161814-49-9 65016
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
37
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
38
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
39
Pravastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81093-37-0 54687
40
Fenofibrate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 49562-28-9 3339
41
Ezetimibe Approved Phase 4,Phase 1,Not Applicable 163222-33-1 150311
42
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 198153-51-4 5360545
43
Ethambutol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 74-55-5 14052 3279
44
Pyrazinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98-96-4 1046
45
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1397-89-3 5280965 14956
46
Calcium Carbonate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 471-34-1
47
Alendronate Approved Phase 4,Phase 3,Phase 2 66376-36-1, 121268-17-5 2088
48
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 142217-69-4 153941
49
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-63-6 5991
50
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757

Interventional clinical trials:

(show top 50) (show all 9540)
# Name Status NCT ID Phase Drugs
1 A Comparison of Virco®TYPE HIV-1 Testing Versus Expert Interpretation of Genotypic Results for Control of HIV-1 Replication Unknown status NCT00840762 Phase 4
2 Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects Unknown status NCT02404233 Phase 4 darunavir/cobicistat;rilpivirine
3 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
4 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
5 Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients Unknown status NCT02008214 Phase 4 Pentoxifylline;Placebo
6 Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects Unknown status NCT00740064 Phase 4 Raltegravir and Abacavir/Lamivudine
7 Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients Unknown status NCT00872417 Phase 4 first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT);second line ARV therapy (3TC+TDF+LPV/RTV)
8 Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients Unknown status NCT01201239 Phase 4 raltegravir
9 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
10 Raltegravir + Lamivudine/Abacavir in HIV/Tuberculosis Co-Infected Patients Unknown status NCT01059422 Phase 4 Raltegravir; Abacavir/Lamivudine
11 Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients Unknown status NCT00135460 Phase 4 nucleoside analogue sparing HAART regimen
12 RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients Unknown status NCT01829802 Phase 4 Ritonavir boosted Atazanavir;Raltegravir;TDF/FTC (or 3TC)
13 The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial Unknown status NCT02401828 Phase 4 Dolutegravir
14 Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients Unknown status NCT02370979 Phase 4
15 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
16 PI Vs. NNRTI Based Therapy for HIV Advanced Disease Unknown status NCT00162643 Phase 4 zidovudine+lamivudine+lopinavir/ritonavir;zidovudine + lamivudine + efavirenz
17 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
18 Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL) Unknown status NCT01875952 Phase 4 Isoniazid
19 Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM Unknown status NCT02844634 Phase 4 Doxycycline 100mg PO daily x 12 months;Tenofovir/emtricitabine 200/300mg PO daily;Doxycycline 100mg PO daily x 6 months
20 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
21 Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients Unknown status NCT01013987 Phase 4 maraviroc;Raltegravir;Darunavir/ritonavir
22 Safety and Efficacy Study Comparing Raltegravir to a Protease Inhibitor in Treatment-naïve, HIV/Hepatitis C Drug Users Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
23 Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection Unknown status NCT01147107 Phase 4 Raltegravir;Efavirenz
24 A Pilot Study of Triple NtRTI/NsRTI Therapy in Antiretroviral Naive HIV-1 Infected Patients Unknown status NCT00199121 Phase 4 Zidovudine (drug)
25 Lopinavir/Ritonavir or Efavirenz as First-line Antiretroviral Therapy Unknown status NCT01049685 Phase 4 First-line Antiretroviral Therapy
26 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
27 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
28 Effect of Maraviroc (MCV) on the Immunological Recovery of HIV-1 Discordant Patients With CD4 Lymphocyte Counts Below 200 Cells/mm3 Unknown status NCT01235013 Phase 4 Maraviroc
29 Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs Unknown status NCT00005000 Phase 4 Nelfinavir mesylate;Efavirenz;Lamivudine;Keyhole-Limpet Hemocyanin;Stavudine;Zidovudine;Didanosine
30 Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection Unknown status NCT02691065 Phase 4 Integrase Inhibitor
31 Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs Unknown status NCT00011895 Phase 4 Abacavir sulfate, Lamivudine and Zidovudine;Efavirenz
32 Effect of a Non-tenofovir, Non-efavirenz-based HIV Regimen on Bone Density and Vitamin D Levels in African-American Patients With HIV Infection Unknown status NCT01343225 Phase 4 atripla;darunavir ritonavir raltegravir
33 Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Patients Unknown status NCT03041051 Phase 4
34 Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine Unknown status NCT00564057 Phase 4 candesartan;lercanidipine
35 Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment Unknown status NCT00005017 Phase 4 Ritonavir;Abacavir sulfate;Amprenavir;Efavirenz;Lamivudine;Stavudine
36 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
37 PrEP Demonstration Project (PRELUDE Study) Unknown status NCT02206555 Phase 4 emtricitabine/tenofovir disoproxil fumarate
38 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Unknown status NCT01813357 Phase 4 Rosuvastatin
39 Once Daily 3TC, Efavirenz and ddI for HIV Infection Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
40 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
41 Atazanavir/r + Lamivudine Dual Therapy Unknown status NCT01599364 Phase 4 Atazanavir, ritonavir, lamivudine
42 Simplification From Protease Inhibitors to Raltegravir Unknown status NCT00941083 Phase 4 Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy);Raltegravir (Use RAL as a simplification strategy)
43 Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Unknown status NCT00843661 Phase 4 ezetimibe;fenofibrate;pravastatin
44 RAltegravir Switch STudy: Effects on Endothelial Recovery Unknown status NCT01453933 Phase 4 raltegravir
45 Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens Unknown status NCT00940771 Phase 4 Boosted Atazanavir
46 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
47 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Unknown status NCT01031069 Phase 4
48 Two Different Treatments 24 vs 48 Weeks Chronic Hepatitis C Genotypes 2 and/or 3 in co-Infected HIV-HCV Unknown status NCT00611819 Phase 4 Peg interferon + Ribavirin;Peg interferon + Ribavirin
49 Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study) Unknown status NCT00120419 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
50 Effects of 2 Initial Standard Antiretroviral Combinations Therapies on Lipid Metabolism Unknown status NCT00759070 Phase 4 Tenofovir + emtricitabine + efavirenz;Tenofovir + emtricitabine + lopinavir/ritonavir

Search NIH Clinical Center for Acquired Immunodeficiency Syndrome

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: acquired immunodeficiency syndrome

Genetic Tests for Acquired Immunodeficiency Syndrome

Anatomical Context for Acquired Immunodeficiency Syndrome

MalaCards organs/tissues related to Acquired Immunodeficiency Syndrome:

42
Testes, T Cells, Liver, Bone, Kidney, Lung, Brain

Publications for Acquired Immunodeficiency Syndrome

Articles related to Acquired Immunodeficiency Syndrome:

(show top 50) (show all 4856)
# Title Authors Year
1
Common oral opportunistic infections in Human Immunodeficiency Virus infection/Acquired Immunodeficiency Syndrome: Changing epidemiology; diagnostic criteria and methods; management protocols. ( 31090147 )
2019
2
Ring enhancing brain lesions in a patient with Acquired Immunodeficiency Syndrome (AIDS): a diagnostic dilemma. ( 31061184 )
2019
3
Antiretroviral activity of Pterois volitans (red lionfish) venom in the early development of human immunodeficiency virus/acquired immunodeficiency syndrome antiretroviral alternative source. ( 31040575 )
2019
4
An immigrant with acquired immunodeficiency syndrome presenting with a rash: A case report. ( 30854204 )
2019
5
Fatal Oculocutaneous Ecthyma Gangrenosum in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome: Case Report and Review of the Literature. ( 30814835 )
2019
6
Consecutive hypoglycemia attacks induced by co-trimoxazole followed by pentamidine in a patient with acquired immunodeficiency syndrome. ( 30170528 )
2019
7
Fecal microbiota transplantation for severe complicated C. difficile colitis in a patient with acquired immunodeficiency syndrome. ( 29449093 )
2019
8
Quality of Life among People Living with Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome in a Anti-Retroviral Therapy Clinic. ( 30739930 )
2019
9
Expression of TLR4 gene is downregulated in acquired immune deficiency syndrome-associated Kaposi's sarcoma. ( 30651761 )
2019
10
Older people living with human immunodeficiency virus/acquired immune deficiency syndrome in Chinese rural areas: perceived stigma and associated factors. ( 31111936 )
2019
11
Total dystrophic onychomycosis caused by Talaromyces marneffei in a patient with Acquired immunodeficiency syndrome on combined anti-retroviral therapy. ( 29251280 )
2018
12
Association of age-related macular degeneration with mortality in patients with AIDS; role of systemic inflammation. ( 30552890 )
2018
13
Restriction Fragment Length Polymorphism-based Genotyping of Toxoplasma gondii from Autopsy-Proven Cases of Acquired Immunodeficiency Syndrome-associated Cerebral Toxoplasmosis. ( 30532352 )
2018
14
Endoscopic resection using argon plasma coagulation for treating esophageal mucosal bridge in a patient with acquired immunodeficiency syndrome. ( 30460905 )
2018
15
Prevalence of arterial hypertension and risk factors among people with acquired immunodeficiency syndrome. ( 30379250 )
2018
16
Adult T-cell leukemia/lymphoma and acquired immunodeficiency syndrome - CD4+ T-cell malignancy in CD4+ T-cell deficient status: A paradox. ( 30303147 )
2018
17
Blood pressure responses after resistance exercise session in women living with human immunodeficiency virus/acquired immunodeficiency syndrome. ( 30276194 )
2018
18
Functional capacity and ventilatory efficiency are preserved in well-controlled people living with human immunodeficiency virus/acquired immunodeficiency syndrome. ( 30276193 )
2018
19
Successful prevention of perinatal HIV transmission utilizing direct observation therapy in the setting of Acquired Immunodeficiency Syndrome (AIDS) and progressive multifocal leukoencephalopathy. ( 30245972 )
2018
20
Cardiac complications in people living with human immunodeficiency virus/acquired immunodeficiency syndrome and their association with CD4+ T-cell count - A cross sectional study. ( 30187022 )
2018
21
Prevalence and factors associated with the use of traditional medicines among human immunodeficiency virus and acquired immunodeficiency syndrome patients in Sokoto, Nigeria. ( 30185681 )
2018
22
Fatal disseminated cytomegalovirus infection with necrotizing oophoritis in a patient with acquired immunodeficiency syndrome. ( 30101134 )
2018
23
Multiple Extradural Spinal Meningiomas in a Patient with Acquired Immunodeficiency Syndrome: Case Report and Literature Review. ( 29966786 )
2018
24
Inpatient Outcomes After Elective Lumbar Spinal Fusion for Patients with Human Immunodeficiency Virus in the Absence of Acquired Immunodeficiency Syndrome. ( 29852306 )
2018
25
Self-care of elderly people after the diagnosis of acquired immunodeficiency syndrome. ( 29791625 )
2018
26
Correlation between Lymphocyte CD4 Count, Treatment Duration, Opportunistic Infection and Cognitive Function in Human Immunodeficiency Virus-Acquired Immunodeficiency Syndrome (HIV-AIDS) Patients. ( 29731931 )
2018
27
Hemophagocytic lymphohistiocytosis (HLH) secondary to disseminated histoplasmosis in the setting of Acquired Immunodeficiency Syndrome (AIDS). ( 29657917 )
2018
28
Prevalence and variables associated with an abnormal ankle-brachial index among patients with human immunodeficiency virus/acquired immunodeficiency syndrome. ( 29649953 )
2018
29
A Case of Jejunal Intussusception caused by Burkitt Lymphoma in an Acquired Immunodeficiency Syndrome Patient. ( 29637755 )
2018
30
Disseminated toxoplasmosis in a patient with advanced acquired immunodeficiency syndrome. ( 29588907 )
2018
31
Intestinal isosporiasis in patients with acquired immunodeficiency syndrome (AIDS). Pathologic diagnosis in small intestinal mucosal biopsies. ( 29566942 )
2018
32
Association of Retinal Vascular Caliber and Age-Related Macular Degeneration in Patients With the Acquired Immunodeficiency Syndrome. ( 29435590 )
2018
33
Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome. ( 29419696 )
2018
34
Positive Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. ( 29362065 )
2018
35
Promoting Cardiovascular Health in Patients Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. ( 29362060 )
2018
36
The Role of Faith-Based Organizations in the Education, Support, and Services for Persons Living with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome. ( 29362058 )
2018
37
Epidemiological situation of acquired immunodeficiency syndrome (AIDS)-related mortality in a municipality in northeastern Brazil. A retrospective cross-sectional study. ( 29340503 )
2018
38
Advantages of Chinese Medicine for Patients with Acquired Immunodeficiency Syndrome in Rural Central China. ( 28887810 )
2018
39
Alterations in the gut microbiota of patients with acquired immune deficiency syndrome. ( 29411528 )
2018
40
Social Representations of health care professionals on Acquired Immune Deficiency Syndrome. ( 30156680 )
2018
41
Case Report: First Coinfection Report of Mixed Leishmania infantum/Leishmania major and Human Immunodeficiency Virus-Acquired Immune Deficiency Syndrome: Report of a Case of Disseminated Cutaneous Leishmaniasis in Iran. ( 29165208 )
2018
42
Histoplasmosis-induced ileal perforation in a patient with acquired immune deficiency syndrome: Case report. ( 30483583 )
2018
43
Acquired immune deficiency syndrome-related epidemic Kaposi sarcoma. ( 30677797 )
2018
44
Risky sexual behaviour and human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) among healthcare workers. ( 29568646 )
2018
45
Human immunodeficiency virus/acquired immune deficiency syndrome: A survey on the knowledge, attitude, and practice among medical professionals at a tertiary health-care institution in Uttarakhand, India. ( 29563671 )
2018
46
Esophagectomy in Patients with Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome: A Viable Option. ( 29747950 )
2018
47
Acquired Immunodeficiency Syndrome A Forensic Perspective. ( 29473812 )
2017
48
Factors affecting antiretroviral treatment adherence among people living with human immunodeficiency virus/acquired immunodeficiency syndrome: A prospective study. ( 29416993 )
2017
49
The End of Acquired Immunodeficiency Syndrome (AIDS) in Singapore - Are We There Yet? ( 29355281 )
2017
50
Imaging Findings of Common Opportunistic Infections and Malignant Tumors in Acquired Immunodeficiency Syndrome Patients. ( 29338829 )
2017

Variations for Acquired Immunodeficiency Syndrome

Expression for Acquired Immunodeficiency Syndrome

Search GEO for disease gene expression data for Acquired Immunodeficiency Syndrome.

Pathways for Acquired Immunodeficiency Syndrome

Pathways related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 B2M CCR2 CCR5 CD4 CSF2 IFNG
2
Show member pathways
13.72 CCR2 CCR5 CD4 CSF2 IFNG IL10
3
Show member pathways
13.44 CCR2 CCR5 CD4 CSF2 IL10 IL2
4
Show member pathways
13.34 CCR2 CCR5 CD4 CSF2 IL10 IL2
5
Show member pathways
13.33 B2M CCR2 CCR5 CD4 CSF2 IFNG
6
Show member pathways
13 B2M CCR5 CD4 CSF2 IL6 MYC
7
Show member pathways
12.93 B2M CD4 IFNG IL10 IL2 IL6
8
Show member pathways
12.66 CD4 IFNG IL10 IL2 TNF
9
Show member pathways
12.64 CD4 IFNG IL10 IL2 IL6 MYC
10
Show member pathways
12.62 CD4 IFNG IL10 IL2 IL6 MYC
11 12.58 B2M CCR2 CD38 IFNG IL10 IL2
12
Show member pathways
12.46 CCR5 CD4 CSF2 IFNG IL10 IL2
13 12.41 CSF2 IL2 IL6 MYC TNF
14
Show member pathways
12.39 ALB IFNG IL2 IL6 TNF
15
Show member pathways
12.37 CCR2 CCR5 CSF2 IFNG IL10 IL2
16
Show member pathways
12.35 CSF2 IFNG IL6 TNF
17
Show member pathways
12.32 IFNG IL10 IL2 IL6 MYC TNF
18
Show member pathways
12.29 CCR5 IFNG IL10 TNF
19 12.27 IFNG IL10 IL6 TNF
20
Show member pathways
12.24 IL10 IL2 IL6 TNF
21 12.22 IFNG IL6 MYC TNF
22
Show member pathways
12.13 CD4 IFNG IL10 IL2 IL6 MYC
23
Show member pathways
12.09 CSF2 IFNG IL6 TNF
24
Show member pathways
12.09 CD4 IFNG IL10 IL2 IL6 TNF
25
Show member pathways
12.05 B2M CCR5 CD4 IFNG IL2
26 12.04 IL10 IL6 MYC TNF
27 11.99 CCR2 IFNG IL2 IL6 MYC TNF
28 11.96 CD38 CD4 CSF2 IL6 TNF
29 11.95 CSF2 IFNG IL10 IL6 TNF
30 11.92 CSF2 IFNG IL6 TNF
31 11.88 CCR2 CCR5 IFNG IL10 IL2 IL6
32 11.87 IFNG MYC TNF
33 11.87 CSF2 IFNG IL2 IL6
34 11.84 CD4 IFNG IL10 IL2 TNF
35 11.83 CSF2 IFNG IL6
36
Show member pathways
11.83 CSF2 IFNG IL2 TNF
37 11.82 CD38 CD4 CSF2 IFNG IL10 IL2
38 11.78 IL10 IL6 TNF
39 11.73 CCR2 CSF2 IL6 TNF
40 11.71 IFNG IL2 MYC
41
Show member pathways
11.71 B2M IFNG IL2 TNF
42
Show member pathways
11.71 CSF2 IFNG IL2 IL6 TNF
43 11.7 CSF2 IFNG IL10 IL2 IL6 TNF
44 11.63 IFNG IL2 IL6 TNF
45 11.61 CD38 CD4 IL10
46 11.6 IFNG IL10 IL6 TNF
47 11.57 CD4 IFNG IL10 IL2
48 11.56 IFNG IL2 TNF
49 11.56 CCR2 IFNG TNF
50 11.52 IFNG IL6 TNF

GO Terms for Acquired Immunodeficiency Syndrome

Cellular components related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.81 ALB B2M CSF2 F9 IFNG IL10
2 external side of plasma membrane GO:0009897 9.65 B2M CCR2 CCR5 CD4 TNF
3 extracellular region GO:0005576 9.65 ALB B2M CSF2 F9 IFNG IL10
4 endoplasmic reticulum lumen GO:0005788 9.02 ALB B2M CD4 F9 IL6

Biological processes related to Acquired Immunodeficiency Syndrome according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.99 CCR2 CCR5 IL10 IL6 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.91 CD4 IFNG IL2 TNF
3 regulation of signaling receptor activity GO:0010469 9.91 CSF2 IFNG IL10 IL2 IL6 TNF
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.88 CCR2 CCR5 CD38 IL2
5 positive regulation of inflammatory response GO:0050729 9.83 CCR2 IL2 TNF
6 response to glucocorticoid GO:0051384 9.82 IL10 IL6 TNF
7 positive regulation of T cell proliferation GO:0042102 9.8 CD4 IL2 IL6
8 MAPK cascade GO:0000165 9.8 CCR5 CSF2 IL2 MYC TNF
9 positive regulation of smooth muscle cell proliferation GO:0048661 9.79 IL6 MYC TNF
10 positive regulation of interferon-gamma production GO:0032729 9.73 CCR2 IL2 TNF
11 negative regulation of bone resorption GO:0045779 9.67 CD38 IL6
12 positive regulation of immunoglobulin secretion GO:0051024 9.67 IL2 IL6
13 positive regulation of podosome assembly GO:0071803 9.66 CSF2 TNF
14 response to molecule of bacterial origin GO:0002237 9.66 B2M IL10
15 cellular response to granulocyte macrophage colony-stimulating factor stimulus GO:0097011 9.65 CD4 CSF2
16 negative regulation of lipid storage GO:0010888 9.65 IL6 TNF
17 cellular response to lipopolysaccharide GO:0071222 9.65 CCR5 CSF2 IL10 IL6 TNF
18 immune response GO:0006955 9.65 CCR2 CCR5 CD4 CSF2 IFNG IL10
19 endothelial cell apoptotic process GO:0072577 9.64 IL10 TNF
20 fusion of virus membrane with host plasma membrane GO:0019064 9.62 CCR5 CD4
21 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.62 CSF2 IFNG IL2 IL6
22 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
23 positive regulation of neuroinflammatory response GO:0150078 9.6 IL6 TNF
24 positive regulation of interleukin-23 production GO:0032747 9.58 CSF2 IFNG
25 entry into host cell GO:0030260 9.55 CCR5 CD4
26 positive regulation of glial cell proliferation GO:0060252 9.54 IL6 MYC TNF
27 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.51 IFNG TNF
28 receptor biosynthetic process GO:0032800 9.49 IL10 TNF
29 regulation of vascular endothelial growth factor production GO:0010574 9.48 CCR2 IL6
30 positive regulation of vitamin D biosynthetic process